BiotechTube

VERU-111 + Enzalutamide, Abiraterone

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Castration-resistant Prostate Cancer

Conditions

Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer

Trial Timeline

Jun 24, 2021 → May 4, 2023

NCT ID
NCT04844749

About VERU-111 + Enzalutamide, Abiraterone

VERU-111 + Enzalutamide, Abiraterone is a phase 3 stage product being developed by Veru for Metastatic Castration-resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04844749. Target conditions include Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04844749Phase 3Terminated

Competing Products

20 competing products in Metastatic Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Veru

VERU-111Phase 3
69
Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or FulvestrantPhase 3
69
Enobosarm + ExemestanePhase 3
69
Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulatorPhase 2
44
Enobosarm + SemaglutidePhase 2
44